Journal
TRANSPLANTATION AND CELLULAR THERAPY
Volume 27, Issue 11, Pages 885-907Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtct.2021.08.016
Keywords
BMT; Cell Therapy; Clinical Trial
Categories
Funding
- National Heart, Lung, and Blood Institute (NHLBI) [U10HL069294, U24HL138660]
- National Cancer Institute (NCI)
- NCI [U24CA76518]
- NHLBI
- National Institute of Allergy and Infectious Diseases
- Health Resources and Services Administration/Department of Health and Human Services [HHSH234200637015C]
Ask authors/readers for more resources
This article summarizes the discussions and recommendations made by 11 committees at the 2021 BMT CTN State of the Science Symposium on hematopoietic stem cell transplant and cell therapy. The committees also considered clinical trial design and inclusion, diversity, and access as cross-cutting themes.
In 2021 the BMT CTN held the 4th State of the Science Symposium where the deliberations of 11 committees concerning major topics pertinent to a particular disease, modality, or complication of transplant, as well as two committees to consider clinical trial design and inclusion, diversity, and access as cross-cutting themes were reviewed. This article summarizes the individual committee reports and their recommendations on the highest priority questions in hematopoietic stem cell transplant and cell therapy to address in multicenter trials. (C) 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
